↩ Go Back
Need help?

Nightclubs for Sale and Investment Opportunities in New York

Nightclubs for Sale and Investment Opportunities in New York. Buy or Invest in a Nightclub, Discotheque, Discobar, Clubhouse, Disco or a Private Bar.

Filters
  • Nightclubs

  • New York

  • Lassi Shop'

 

There were no results matching your filter criteria. Edit filters or checkout recent listings below.
Interested in businesses matching this criteria? Register your requirements below and we'll keep you posted when a matching business registers.

Create Investor Profile

Bio Therapeutic Drugs Business Investment Opportunity in Manlius, United States

Company developing diagnostics & therapeutics for skin cancer: basal cell carcinoma, squamous cell carcinoma, melanoma.
- The company currently works with pharmaceutical and diagnostic companies, research institutes, CROs, and CDMOs to help them develop molecular bioassays and digital pathology products, and to visualize and analyze the resultant data via AI and ML for the benefit of patients, their family, and their healthcare providers. - Currently, has 3 clients: Klotho Therapeutics Inc. (a biotechnology company in San Diego, CA, USA), Unger Medical PC (a hair restoration medical practice in NY, NY, USA), and Astrix Technology Group (a life sciences strategy, technology, and staffing services company based in Red Bank, NJ, USA). • Target Market: - The business is specialized in developing diagnostics and therapeutics for human basal cell carcinoma, squamous cell carcinoma, and melanoma. This skin cancer group comprises the most diagnosed cancers worldwide of all cancer types with over five million cases diagnosed each year. - The skin cancer therapeutics diagnostics and therapeutics products industry worldwide were worth $8.2 billion USD in 2019 and is projected to reach $15 billion by 2027. This represents a CAGR of 7.5%. - What share of the total skin cancer target market can we estimate is realistic for to obtain? A conservative estimate is that our company should be able to reach $150 million USD in annual revenues by the close of 2028. • Problem or Need: - The main project involves the development of a Skin Cancer Patient Data Blockchain. - Currently there is a serious problem concerning how oncology patients organize and share their medical data, how companies get access to this data, and a lack of return in value to the patients for sharing their personal data. The blockchain is designed to tackle and solve these problems. - The blockchain for skin cancer patients will be comprised of multiple decentralized nodes contributing data to a shared ledger where patients can set up smart contracts to share and control their data. - Skin cancer patients will be able to share their data with research institutions, drug companies, diagnostic companies, contract research organizations, client trials organizers, and other stakeholders. - Also, planning to launch a medium of exchange within the blockchain system to allow patients to be given money for participation in the sharing of their data with the mentioned company stakeholders. - Therefore, the company stakeholders that plan to utilize the patient’s data would provide revenues and income to support the operations of the blockchain. - For example, pharmaceutical companies would be important customers that the business would cultivate as users of the patient’s healthcare data. This is because pharma companies can use this blockchain to discover patients with the right profile for a skin cancer clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. This should greatly streamline for the pharma company the time it takes to enroll the right patients into clinical trials and get them started. • Solution: - What is the core value proposition? For the company stakeholders in the skin cancer patient blockchain, the business is hoping to demonstrate that this blockchain technology will be a way to improve business outcomes through better efficiency, risk management, and security. - For these customers, this will enable them to maintain and capture new sources of profit. At the same time, company stakeholder participation will also grow the business as the integrator and host of the blockchain and result in significant profit growth for the company. • Team: The team is comprised of: - Founder, President, and CEO, a 100% full-time permanent employee has a Ph. D. in Cell and Molecular Biology from St. John’s University (New York, NY), a M. S. in Microbiology & Immunology from Long Island University, and a M. B. A. from Le Moyne College. In addition, he has 20 years of quality assurance and regulatory affairs experience at the Bristol-Myers Squibb Company, Charles Rivers Laboratories, and Vybion, Inc. This includes moving numerous human therapeutic products from R&D, through clinical trials, and into the marketplace via approval by the US FDA and worldwide regulatory bodies. In addition to the above experience, and an addition 18 year of experience in human therapeutics research and development and in the management of laboratory-based cell culture, toxicological, or bioassay projects within the biopharmaceuticals industry. However, he is a Senior Member of the food, drugs & cosmetics section of the American Society for Quality (ASQ), and a society member of The American Association for the Advancement of Science (AAAS). - The President of Hillberg Consulting is a part-time, non-permanent hourly contract employee of R&D department. She is an accomplished executive and board member with a reputation for delivering bottom-line profitability while building the infrastructure to support growth and success. She has served at Johnson & Johnson Ortho Clinical Diagnostics as VP of R&D, and as Chief Technology, Officer at Carestream Health. Holly has a B. S. in Chemical Engineering from Michigan Technology University and a M. S. in Electrical Engineering from Rochester Institute of Technology. - Marketing Consultant - part-time, non-permanent hourly employee. He is a professional engineer and entrepreneurial executive with focus on emerging technology solutions applied to real world problems. He has substantial experience in team building and in developing market strategies & partnerships. This includes over two decades of technology & networks business planning, development, & implementation. He has a Masters in Entrepreneurial Studies - MIT Sloan School of Management, and M. S. & B. S. in Engineering from Syracuse U. and Utica College. - Blockchain Development Technical Project Management Consultant - Part-time, non-permanent hourly employee that is a contractor from EffectiveSoft Corporation, San Diego, CA. She has eight years of experience as VP of Service Delivery and as the Head of Sales for enterprise level software solutions at Effective Soft Corp. She has a M. B. A. from The University of Manchester and a B. S. degree from Minsk State Linguistics U. – Legal Counsel - Part-time, non-permanent hourly contract employee. He holds the Juris Doctor from Boston College Law School, and B. A. in Political Science from Binghamton University. He is a Partner at Newman & Lickstein, with eight years of experience in representing technology companies and investors in licensing, IP development, real estate, mergers & acquisitions, and business litigation. - Demonstrating results to stakeholders will be the key to success. For skin cancer, there is a lot of data collected from various heterogeneous sources – pathology imaging data, genetic testing, surgery, drugs intervention, payer, and insurance information, etc. - Some companies are using a website or app to meet the social needs of patients to discuss their concerns with other patients or a few qualified physicians. No competitor is comprehensively focusing on skin cancer data & treatment to the level that we do. Possible competitors have thus not yet integrated the patient data, shared consent, and the patient monetization blocks together into a comprehensive and workable blockchain system for skin cancer patients, or for any segment of the oncology market, for that matter. - This team, on the other hand, has decades of experience in oncology research, the development of products and services for cancer patients, in oncology clinical biomedicine and in oncology marketing, and that makes the company well-equipped to solve the problems around skin cancer patient data acquisition, its organization, and its beneficial use for the patients and for their healthcare providers. For example, regarding the latter, the company also harnesses artificial intelligence (AI) and machine learning (ML) to extract relevant data from the patient’s database that will help healthcare providers to better understand the patient’s tumor and the tumor microenvironment (i. e. , tumor growth, cellular migration, blood supply to the tumor, subcellular trafficking, and tumor metastasis), drug efficacy (including drug penetration into the tumor, possible tumor shrinkage or tumor death, and drug toxicity, and side effects), or the immediate or long term results of surgical intervention. - When competitors enter this specific market, the business plans to stand out by utilizing a value-based strategy that clearly displays our brand and the above competitive advantage. • Traction: - Currently works with pharmaceutical and diagnostic companies, research institutes, and contract research development and manufacturing companies to help them obtain and organize their molecular bioassays and pathology data. We propose to utilize this traction and intercompany personal connections to gain and grow customers that will use and pay for patient data on the blockchain. - Also use social media & patient advocacy organization to recommend the blockchain to skin cancer patients so that we can grow the patient database. - The company is also a member of the Hyperledger Foundation Healthcare Special Interest Group. Hyperledger, as part of the Linux Foundation, provides technology leaders a uniquely open and collaborative international community from which to develop, validate, and field enterprise-grade blockchain technology solutions. It is the mandate of the Hyperledger Healthcare Special Interest Group (HC-SIG) to represent healthcare professionals and technologists, to globally unite these individuals, and to advance the state of the healthcare industry through the implementation of technology solutions using blockchain technologies in general, and the umbrella of Hyperledger frameworks and toolsets specifically. • Revenue Model: - Within the ecosystem surrounding the above patients, who would buy/lease the skin cancer blockchain services that the company wish to market? In this blockchain system, individuals will be allowed to store and monetize their own health data including blood test results, medical history, genetic profile, skin photographs, pathology images and other sensitive information. - In the healthcare marketplace, cancer patients would be paid in stablecoin currency to lease their individual data to companies for a certain amount of time. - Pharmaceutical (pharma) companies would be important customers that the company would cultivate as users of the patient’s permitted healthcare data. - Blockchain can help pharma companies discover patients with the right profile for a clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. - According to Milind Kamkolkar, chief data officer at Sanofi, patients could be prompted based on their data to join a clinical trial, thereby also accelerating the process and accuracy of trial recruitment. Using this blockchain if a person declines, no personal information will be shared, and the person's identity will remain private. If the person agrees, the overall process will move faster by abolishing the need for intermediaries. - For pharma companies, better inclusion in clinical trials and better reproducibility for studies can reduce the time and money needed to develop new drugs. - Besides pharma companies, research institutes will be willing to pay for the data from skin cancer patients, and the introduction of our blockchain-based data ecosystem may help ensure that the individuals take control over their data and companies and research institutions may acquire data more freely after the latter have obtained consent from individual patients. - How are the products and services going to generate revenue? The most straightforward way to generate revenue is to have the blockchain client customers pay for the products and services that exceeds by a large margin what it costs to develop and operate the blockchain (a cost-plus strategy). - When competitors enter this specific market, plan to stand out by utilizing a value-based strategy that clearly displays the brand and competitive advantage. • Market Projections: - What share of the total skin cancer blockchain target market can we estimate is realistic for to obtain? The global skin cancer blockchain customer market size stood at USD 8.19 billion in 2019 and is projected to reach USD 14.55 billion by 2027, exhibiting a CAGR of 7.5% during the forecast period. A conservative estimate is that the company should be able to reach $150 million in annual revenues in 4 years. - These financial projections would be possible because of the company participating and partnering with individuals and companies within the oncology community to create superior value for the products and services. - Over the next 4 years, the company anticipates receiving funding from investors, and revenues from pharmaceutical companies and research institute customers. - However, expenditures are also expected to increase. Expenses incurred will be for the development of products and services, and for personnel, equipment, supplies, business development & marketing. • Competition: - Have identified Nebula Genomics and Longenesis as competition. These two leading firms in artificial intelligence and blockchain technology for healthcare, are developing a platform for the storage and exchange of genomic data. - Nebula Genomics is a San Francisco-based biotechnical company that uses blockchain to “build a marketplace” for clinical genetics data. - Longenesis is a Hong Kong-based partnership between Insilico Medicine and the Bitfury Group, which makes blockchain platforms for the exchange of health data. - The above companies will reportedly apply artificial intelligence and blockchain technology to develop a platform for individuals and large data providers to store, manage, exchange, and profit from genomic and other types of clinical data. To automate data acquisition, the project developed by both Nebula Genomics and Longenesis will utilize smart contracts. - Unlike the Nebula Genomics and Longenesis blockchains, this blockchain project will be focused on oncology patients and the ecosystem around them rather than on a multitude of disease sectors. - In addition to Nebula Genomics and Longenesis, the U. S. -based life science research marketplace, Scientist. com, has revealed the development of a pharmaceuticals blockchain platform. This latter blockchain-powered platform is reportedly designed to track and protect pharmaceutical data. Thus, the Scientist. com DataSmart TM platform enables pharmaceutical and biotech companies to demonstrate that critical supplier information and important research data has not been tampered with and remains unaltered before submission to regulators such as the FDA and the EMEA. - However, the above platforms do not adequately address the pressing concerns of cancer patients regarding the control and sharing of their personal data. Competitive Advantage: • Strategy. Specifically for oncology blockchain products, the major company players that may join our blockchain to gain access to data from skin cancer patients include: Almirall S. A. Amgen, Inc. Boehringer Ingelheim GmbH. Bristol-Myers Squibb Company. Eli Lilly and Company. Elekta AB. F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc. Merck & Co. , Inc. Mylan NV. Novartis AG. Pfizer. Regeneron. Sanofi. Sun Pharmaceutical Industries Ltd. Varian Medical Systems, Inc. Sensus Healthcare. ICAD, Inc. Accuray, Inc.
Company developing diagnostics & therapeutics for skin cancer: basal cell carcinoma, squamous cell carcinoma, melanoma.
9.5   Manlius
Run Rate Sales
USD 26 thousand
EBITDA Margin
35 %
Financial Investment
USD 1 Mn for 25%
Contact Business

Consulting Company Investment Opportunity in New York, United States

Consulting business with empowering prosperity seeks investment.
Innovation Network: Over 6,000 members in our innovation network, fostering collaboration, idea exchange, and collective progress. Global Impact: Member of UN Women Compact, demonstrating our commitment to gender equality and empowerment on a global scale. USAID and UN approved contractor. Member of Climate Finance Network. Leadership Recognition: Select Global Women in Tech Mentor, showcasing our dedication to nurturing and supporting women leaders in the technology sector. Global Outreach: Reaching over 1,000 leaders worldwide, establishing a significant and influential presence in various sectors.
6.8   New York
Run Rate Sales
USD 180 thousand
EBITDA Margin
40 %
Financial Investment
USD 150 K for 30%
Contact Business

Profitable Event Management Company for Sale in New York, United States

New-York based enterprise tech executive networking organization and brand, working with the Fortune 500 companies.
- A private networking organization for the world’s leading tech executives. - Helps participants gain insights from their peers, network with world’s leading executives, develop partnerships, and learn about critical technologies through in-person gatherings, virtual roundtables, and ongoing executive collaboration programs. - Programs and engagements are closed-door, invite-only with no media, nor recordings. - Currently, working with the Fortune 500 tech executives. - Connected with over 150 large enterprises throughout the US. - Focused around technology, data and innovation. - All verticals covered but high participation from executives at top banks, financial services & insurance enterprises. - Top clients include IBM, Fujitsu, Google, SAP and many more. - Currently operating on a per event cost basis.
8.7   New York
Run Rate Sales
USD 180 thousand
EBITDA Margin
40 %
Business for Sale
USD 350 K
Contact Business

Profitable Robot Manufacturing Company Investment Opportunity in New York, United States

New York based company involved in research, development, manufacturing of robots with 50 major clients.
- New York based company involved in research and development, manufacturing and sales of robot and related technologies. - Serving over 50 major clients worldwide, including leading tech companies, manufacturing giants, and research institutions. Most of our clients are based in European countries. - There are 2 revenue channels, one is through sales of robots and the other is through working on projects. - We manufacture based on the orders we get. Get about 15 orders per month. Average value of each robot is USD 100k. - The projects we work on are vacuum robot project, gimbal robot project, pepper bot etc and R&D. - We get about 5 to 6 projects a year. Average duration of 1 project is 2 to 3 years. Average value of 1 project is USD 500k. - Additionally, we also provide robotics courses. - The company has experienced rapid growth since its inception, with an average annual growth rate of 30% over the past five years, showcasing its strong market presence and demand for innovative robotic solutions. - The business has 89 permanent employees, involved in R & D, sales, marketing, admin etc. No contract employees are hired.
New York based company involved in research, development, manufacturing of robots with 50 major clients.
7.0   New York
Run Rate Sales
USD 12 million
EBITDA Margin
40 %
Financial Investment
USD 5 Mn for 50%
Contact Business

Restaurant Investment Opportunity in New York, United States

Korean restaurant in Flushing, New York with a growing demand seeks an investor.
- Based on authentic and healthy foods. - 1,800 customers served and a growing demand for dine-in. - High revenue growth despite lack of financial resources. - We opened right before Covid-19. - Seeking an investor to capitalize on the growing demand and take the business to the next level.
7.5   New York
Run Rate Sales
USD 456 thousand
EBITDA Margin
Operating at loss
Financial Investment
USD 50 K for 50%
Contact Business

Debt Collection Agency for Sale in Mineola, United States

For Sale: One of largest judgment recovery business catering to 100 clients in east Texas.
- Already has USD 1.6 million in outstanding judgments. - Currently catering to around 100 clients from banking and other service-based industries. - We generate revenue by charging a commission of 25-30%. - Developed defendant targeting and recovery process. - The company is not required to be registered under the financial regulator of the country since it is just a debt collection agency and does not provide any financial services like loans.
5.7   Mineola
Run Rate Sales
USD 42 thousand
EBITDA Margin
32 %
Business for Sale
USD 175 K
Contact Business

Beauty Clinic for Sale in New York, United States

Beautiful and modern medical spa set-up for skin care and laser treatments in great location.
• Established business with existing clients located in a high-traffic area in Franklin Square. • Professional medical spa offering a variety of services including facials, body contouring, microdermabrasion, chemical peels, cool sculpting, and laser treatments. • Have additional services such as a tattoo for permanent makeup. • Have 1500 square feet of space with parking in rear. • Beautiful buildout with reception area, 5 treatment rooms, waiting area, office, billing area and a full basement. • Potential for a new owner to take advantage of the existing customers and expand the business. • Highly sought-after industry in the area, with a potential to increase customer base and revenue. • Owner is taking care of the business for now with the help of part time staff.
Beautiful and modern medical spa set-up for skin care and laser treatments in great location.
6.5   New York
Run Rate Sales
USD 180 thousand
EBITDA Margin
25 %
Business for Sale
USD 340 K
Contact Business

Healthcare Portal Investment Opportunity in New York, United States

Platform connecting healthcare providers and meeting providers seeks investment.
- Our platform enables a constantly expanding network of healthcare professionals to find, book, and pay for courses, conferences, hands-on training, and other offers from healthcare institutions. - Intended audience will be able to look for the event based on their career, area of expertise, and location, and can then book and pay from any location. The user may reach a larger audience, sell more seats, and increase their earnings by simply listing the event on our platform. - The user will have easy access to your selling process in real-time, the figures you need to follow, and the ability to track and examine your sales at any time, anywhere. - We are looking to generate revenue by charging subscription fees for listing on the platform.
7.0   New York
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 1 Mn for 5%
Contact Business

IT Consultancy Company Investment Opportunity in New York, United States

Unique IT consultancy with custom software, five US data centers, and 12,000 users.
- 100 customers, 12,000 network users, and data centers in five US locations. - Wholly owned autonomous network and infrastructure. - Custom software developed for automating customer qualification and acquisition. - Two employees with the remainder of the staff being independent contractors.
Unique IT consultancy with custom software, five US data centers, and 12,000 users.
7.6   New York
Run Rate Sales
USD 300 thousand
EBITDA Margin
Nil
Financial Investment
USD 250 K for 25%
Contact Business

Newly Established Bakery Investment Opportunity in New York, United States

Seeks Investment: Bakery start-up that will generate majority part of its revenue from B2C segment.
- We are just starting and creating a small production facility for selling online and delivering our products to shops and supermarkets. - Over time we plan to open a coffee shop in which an exhibition of paintings by artists (mainly American) will be exhibited. - We will cater to both B2B, and B2C segment. The majority of our revenue will be from the B2C segment and through the online mode. - There is only one shareholder with complete ownership of the business. - We have already invested in the equipment for the business and will be starting operations in a few months.
6.3   New York
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 150 K for 15%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in New York, United States

Generic complex injectable pharmaceutical manufacturer with 5 drugs pending approval and proven track record.
- The two main partners sold their stake in a previous company almost 10 years back and have now created their own new company. - They hold over 40 patents and are on the verge of their first approved generic complex injectable drug in a couple of months. - The facility was inspected very recently by the FDA and passed. - We have 5 drugs pending approval with a total market value of over USD 4B and only a few competitors. - The company should be worth USD 2B in another 3 years. - The business has not generated any revenue because we have been in the process of R&D in developing these drugs for the past 6 years and have invested over USD 40 million in the business.
Generic complex injectable pharmaceutical manufacturer with 5 drugs pending approval and proven track record.
7.4   New York
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 20 Mn for 5%
Contact Business

Virtual & Augmented Reality Company Investment Opportunity in New York, United States

Computer vision coaching platform and hardware product with 100 users seek investment.
- We have 100 users currently. - Since the product is in the pre-sales stage, we do not have many users. - Our product was still under development stage last year. - The promoter has 20+ years of experience. - We have 15 contract-based employees and 4 permanent employees.
7.5   New York
Run Rate Sales
USD 3.5 million
EBITDA Margin
40 %
Financial Investment
USD 3 Mn for 33%
Contact Business

Cosmetic Franchise Opportunity

Radiant Melanin London Limited, Established in 2017, 2 Franchisees, London Headquartered
  • 300+ Page Views
  • 100+ Investor Views
- Skincare brand based in the UK and currently looking to expand in other countries through franchising and distributorship. Currently have a store in Paris and London. - The products are manufactured in-house in the United Kingdom. - We do sales of GBP 25k per month in Paris, and GBP 15k in London. - Most of our sales in London are online. - We offer a 50% margin on products to our distributors and franchisee. - The business does not charge any royalty from the franchisee. - The business offers services like acne facials in their store thus enhancing their sales. - The brand is luxurious and comes with classy packaging.
Radiant Melanin London Limited, Established in 2017, 2 Franchisees, London Headquartered
7.1   Expanding in New York
Exp Monthly Sales
USD 30 thousand
Space Required
500 - 1500 Sq Ft
Investment Required
USD 277 - 629 K
Contact Company

Profitable Robot Manufacturing Company Investment Opportunity in New York, United States

Gulf-based robotics company seeking investment to start robotic academy and sales showroom in the USA.
- This company started as a self-funded enterprise in Dubai and has grown into a highly profitable robotics company with local and international communities. - We have three business operations- - Training programs for students and working professionals interested in robotics. - We rent highly secured and highly sophisticated humanoid robots to the hotel and restaurant industry and corporate sector offices. - Have our own research and development in developing a fully functional humanoid smart AI robot and have manufacturing based out of China. - Currently, our operations are based out of Dubai, but we are planning to transfer the business operations, employees, and financials to our new business set up in New York. - The revenue mentioned in the profile is only from our educational business since we are only planning to transfer that. - We are providing STEM pro-level courses to working professionals and offering an in-house jobs to highly skilled candidates. - Around 1,250+ students have been enrolled in our courses. - We provide live and recorded classes. - The transfer will be complete when we successfully collaborate with a local partner. - In addition to 8 permanent employees, who will be transferred to of new business set up in New York, we also have 70 freelancers working with us. - The investor will only get a stake in the business set-up in New York.
7.2   New York
Run Rate Sales
USD 1 million
EBITDA Margin
30 - 40 %
Financial Investment
USD 340 K for 40%
Contact Business

Liquor Store Seeking Loan in Syracuse, United States

Craft beer distribution company with 2 LOB - D2C e-commerce and traditional retail distribution.
The business is currently working with 30 suppliers (breweries) and we have an extensive online marketplace. We take a supplying brewery's brand under our brand portfolio and then distribute their products. Unfortunately, suppliers are being turned away at this time until we can achieve scale. Interest in our unique service is extensive.
Craft beer distribution company with 2 LOB - D2C e-commerce and traditional retail distribution.
6.0   Syracuse
Run Rate Sales
USD 120 thousand
EBITDA Margin
Nil
Business Loan
USD 250 K at 10%
Contact Business

Frequently
Asked
Questions

  • What level of due diligence does SMERGERS conduct on the businesses/member?

    SMERGERS scrutinizes all profiles and only features a select group of businesses, investors, advisors that meet a basic requirement. When required, certain members may have submitted some form of proof …read more

  • How active are the business profiles listed on SMERGERS?

    We regularly filter out businesses which are inactive or have already closed a transaction. Typically, if the business is actively looking to sell/raise capital, the status is shown in green.

  • How can I be sure about privacy and confidentiality?

    We understand the level of confidentiality required in strategic transactions and we strive to provide a safe and secure experience for our members. Please review our privacy policy. We …read more

  • How can I contact a business listed on SMERGERS?

    You need to be logged in before you connect with a business. Click here to register and message the business If you are already logged in, please use the contact …read more

  • Should you buy an existing business or start a business from scratch?

    Buying an existing business is generally an easier way to start a business with an immediate head start. It saves valuable time and administrative efforts, considering starting from scratch is …read more

  • How successful has SMERGERS been in helping its users successfully close a deal?

    SMERGERS is a discovery and matchmaking platform with a global reach. It helps in connecting Businesses, Investors, Acquirers, Lenders, M&A Advisors and Boutique Investment Banks across locations, industries and transactions. …read more

  • Show more